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Background: Pathological stage III/N2 non-small cell lung cancer (NSCLC) is heterogeneous, and the optimal
prognostic marker for survival remains unclear in Chinese patients. The aim of the present study was to assess the
prognostic value of the clinicopathologic features and excision repair cross-complementing group-1 (ERCC1) in
resected p-stage III/N2 NSCLC patients that received cisplatin-based adjuvant chemotherapy.
Methods: Clinical data concerning 115 patients with histopathologically confirmed stage III/N2 NSCLC who
underwent a complete resection were reviewed retrospectively. All patients received cisplatin-based adjuvant
chemotherapy. The protein expression levels for ERCC1 were immunohistochemically examined in 115 patients. The
relationship between the ERCC1 protein expression level and the clinical outcomes of the patients was then
observed.
Results: The 5-year survival rate and median survival time of patients with pathological stage III/N2 NSCLC after
surgery and postoperative chemotherapy was 27.0% and 28.0 months, respectively. Survival of patients with ERCC1
negative tumors was significantly longer than those with ERCC1 positive tumors (p = 0.004). However, it was not
entirely clear whether adjuvant chemotherapy with cisplatin-based agents was beneficial for ERCC1-negative
patients with p-stage III/N2. A multivariate analysis of survival in patients with stage III/N2 NSCLC showed that surgical
procedure (pneumonectomy vs. lobectomy; p = 0.001), number of involved lymph nodes (≤5 vs. >5; p = 0.001) and
ERCC1 protein expression (negative vs. positive; p = 0.012) were significant prognostic factors. In addition, the
prognosis of patients with skip mediastinal lymph node metastasis showed a tendency for improved survival, but
this was no significant (p = 0.432).
Conclusions: Findings from this retrospective study suggested that the number of involved lymph nodes and the
type of pulmonary resection are significant and independent prognosis factors in patients with p-stage III/N2 NSCLC.
In addition, it was found that ERCC1 protein expression might play an important role in the prognosis of
p-stage III/N2 NSCLC patients treated with cisplatin-based adjuvant chemotherapy.
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Table 1 Clinicopathological factors and ERCC1 protein
expression
Characteristics No. of cases







≤65 years 69 (60.0%) 42 (60.9%) 27 (39.1%) 0.814
>65 years 46 (40.0%) 29 (63.0%) 17 (37.0%)
Gender
Female 34 (29.6%) 17 (50.0%) 17 (50.0%) 0.093
Male 81 (70.4%) 54 (66.7%) 27 (33.3%)
Smoking
Ever 74 (64.3%) 44 (59.5%) 30 (40.5%) 0.499
Never 41 (35.7%) 27 (65.9%) 14 (34.1%)
Histology type
Adenocarcinoma 78 (67.8%) 52 (66.7%) 26 (33.3%) 0.114
Others 37 (32.2%) 19 (51.4%) 18 (48.6%)
Pathological-stage
IIIA 105 (91.3%) 67 (63.8%) 38 (36.2%) 0.178
IIIB 10 (8.7%) 4 (40.0%) 6 (60.0%)
T factor
T1、T2 83 (72.2%) 48 (57.8%) 35 (42.2%) 0.165
T3、T4 32 (27.8%) 23 (71.9%) 9 (28.1%)
Operative procedure
Pneumonectomy 25 (21.7%) 15 (60.0%) 10 (40.0%) 0.840
Lobectomy 90 (78.3%) 56 (62.2%) 34 (37.8%)
Number of involved
lymph nodes (N1+N2)
≤5 59 (51.3%) 32 (54.2%) 27 (45.8%) 0.089
>5 56 (48.7%) 39 (69.6%) 17 (30.4%)
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Because of its aggressiveness, lung cancer is often in
an advanced stage by the time it is diagnosed. The
range in the survival of patients with pathological
stage III/N2 locally advanced NSCLC associated with
various prognostic factors suggests that they are a
heterogeneous group [1,2]. Many studies have evalu-
ated the validity of various prognostic factors among
p-N2 NSCLC patients in order to establish a treat-
ment strategy [3-5]. However, some reports conflict,
and in general the associations do not appear suffi-
ciently strong to be of value in formulating a clinical
treatment plan. Recent studies have investigated a
number of tumor biomarkers for prognostic and pre-
dictive utility when considering systemic therapy and
the most prominent amongst these is the excision re-
pair cross-complementation group 1 (ERCC1) protein.
ERCC1 is one of the key enzymes of the nucleotide
excision repair pathway, which is essential for the re-
moval of platinum-DNA adducts. Recent studies have
demonstrated that the expression levels of ERCC1 are
related to a survival benefit from cisplatin-based chemo-
therapy among patients with advanced NSCLC [6-8].
In an adjuvant setting, patients with ERCC1-negative
tumors exhibited prolonged survival relative to those
with ERCC1-postive tumors. These findings suggest
that ERCC1 expression is a double-edged sword in
NSCLC, simultaneously being a significant and inde-
pendent prognostic factor of survival in NSCLC and
also being associated with increased resistance to
platinum-based chemotherapy [9-14].
In the present study, we retrospectively investigated
whether the clinicopathologic factors and the expression
levels of ERCC1 in tumor tissue, measured using immu-
nohistochemical staining, were associated with prognosis




Patients with histopathologically confirmed stage III/N2
NSCLC who underwent a complete resection, either by
means of lobectomy or pneumonectomy, and were ad-
ministered with postoperative systemic chemotherapy
were evaluated retrospectively between January 2005 and
December 2009 at Beijing Chao-Yang Hospital, China.
Mediastinal lymphadenectomy was routinely performed.
The postoperative chemotherapy regimen was cisplatin
at a dose of 75 mg/m2 on day 1 plus gemcitabine at a
dose of 1250 mg/m2 on days 1 and 8 every 3 weeks (GP),
or cisplatin at a dose of 75 mg/m2 on day 1 plus pacli-
taxel at a dose of 175 mg/m2 on day 1 every 3 weeks (TP)
[15]. The patients who had received preoperative therapy
were excluded.Resected specimens were sent to our pathology depart-
ment for histopathological and immunohistochemical
examination. The histopathological findings were classified
according to the World Health Organization criteria, and
the AJCC TNM staging system (7th edition) was also
employed [16,17]. Skip metastasis is lymph node metastasis
that skips lymph node stations that are in close proximity
and occurs at a considerable distance from the primary
tumor. Lymph node metastases from lung cancer may skip
the intralobar lymph nodes and move directly to the medi-
astinum. In our study, skip mediastinal lymph node metas-
tasis was defined as mediastinal lymph node metastasis
(N2) without peribronchial and/or hilar lymph node metas-
tasis (N1). The preoperative assessments included chest
roentgenography and computed tomography (CT) of the
chest and upper abdomen. Clinical N2 status was defined
by the presence of a lymph node measuring more than
1 cm in short axis diameter. Bone scintigraphy was
performed to detect bone metastasis. Magnetic reson-
ance imaging of the brain was routinely employed for
Figure 1 Examples of ERCC1-expression scores obtained using immunohistochemical analysis. Score 0 (A), 1 (B), 2 (C) and 3 (D) correspond
to none, weak, moderate, and strong, respectively.
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routinely performed to obtain a pathological diagno-
sis using transbronchial lung biopsy, and to evaluate
endobronchial staging.
Follow-up information was obtained from all patients
through office visits or telephone interviews, either with the
patient or with a relative. The patients were evaluated everyFigure 2 Overall survival curves after surgery in p-N2 patients accord
rates of patients with ≤5 positive lymph nodes and >5 positive lymph nod3 months using chest roentgenography, and chest CT scans
were performed every 6 months for the first 2 years after
surgery and annually thereafter. The survival period was
calculated using the day of lung resection as the first day,
and the day of death or the last follow-up as the last day.
The patients’ records including their clinical data,
preoperative examination results, details of any surgeries,ing to the numbers of involved lymph nodes. The 5-year survival
es were 40.2% and 20.0%, respectively.
Table 2 Evaluation of patient survival using univariate
analysis (log-rank test)
Characteristics n 5-Year survival (%) p-Value
Age
≤65 years 69 27.2
0.981
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tients were also reviewed.
Immunohistochemical staining
A total of 115 human stage III/N2 lung cancer specimens
were obtained. The patients were fully informed and gave
their consent for collection of clinical samples. The pri-
mary tumor was resected and specimens were fixed in
10% formalin and embedded in paraffin. The longest
diameter of the tumors was measured, and one or two
5-μm thick sections were obtained for each centimeter
of the tumor from the areas containing viable tumor
tissue at a maximum ratio with no (or minimum)
hemorrhages or necrosis. Antigen retrieval was performed
by adding citrate buffer (pH 6.0) and heating in a micro-
wave oven (20 minutes at 100°C). All of the procedures
were performed in accordance with the antibody manufac-
turers’ protocols. The primary tumor sections were incu-
bated with anti-ERCC1 primary antibodies at a 1:100
dilution (8F1: Thermo-Lab Vision). The reaction was vi-
sualized using a 3, 3-diaminbenzidine (DAB: Roche) sub-
strate system. Then contrast staining was performed using
Mayer’s hematoxylin.
Evaluation of the ERCC1 expression level
ERCC1 staining was independently evaluated under a
light microscope at a magnification of ×400 by two pa-
thologists who were blinded to the clinical data. Tumor
nuclear staining intensity was graded on a scale of 0–3.
The percentage of positive tumor nuclei was evaluated,
and a proportion score was attributed (0 if 0%; 0.1 if
1%–9%; 0.5 if 10%–49%; and 1.0 if ≥50%), as previously
described [10]. The intensity and proportion scores were
then multiplied to give the semiquantitative H-score.
The median value of all of the H scores was chosen a
priori as the cutoff point for separating ERCC1-positive
tumors from ERCC1-negative tumors.
Statistical analysis
Cases were evaluated for demographic, surgical, and patho-
logical variables, and the distributions of these variables
were compared using the χ2 test or Fisher’s exact test. Pa-
tient survival was analyzed by means of the Kaplan–Meier
method, using time zero as the date of thoracotomy and
death as the endpoint. Differences in survival were deter-
mined using the log-rank test for univariate analysis, and
prognostic factors were included in a multivariate analysis
using the Cox proportional hazards regression model. Re-
sults were considered significant at p < 0.05.
Results
A total of 115 patients met the enrollment criteria
and were entered into the study from January 2005 to
December 2009 at the Beijing Chao-Yang Hospital, China.The patients included 81 males and 34 females. The me-
dian age of all patients was 62 years (ranging from 33–80
years). Seventy four patients (64.3%) had a smoking habit.
The histological types included 78 adenocarcinomas
(67.8%), 30 squamous cell carcinomas (26.1%) and 7 large
cell carcinomas (6.1%). There were 29 patients graded as
T1, 54 as T2, 22 as T3, and 10 as T4 (stage IIIB). A pneu-
monectomy was performed in 25 (21.7%), and a lobectomy
in 90 (78.3%). The average number of dissected lymph
nodes (N1 and N2) was 20.0 (range: 5–42). The average
number of involved lymph nodes (N1 and N2) was 5.0
(range: 1–24). Skip mediastinal lymph node metastasis
(N1 negative) was demonstrated in 34 patients (29.6%),
and mediastinal lymph node metastasis with N1 disease
(N1 positive) was found in 81 patients. During this
study, 76 patients received the GP chemotherapy regi-
men, and 39 patients received the TP chemotherapy
regimen for 4 to 6 cycles, respectively. Patient characteris-
tics are presented in Table 1. ERCC1-positive expression
(H score ≥1.0) was observed in 71 of the 115 tumors exam-
ined using immunohistochemical staining. Examples of the
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Figure 1. The relationship between the immunohistochem-
ical staining patterns and the clinicopathological factors
were examined (Table 1). No significant associations were
found between the ERCC1 expression status and age, sex,
smoking, pathological stage, operative procedure, or the
number of involved lymph nodes.
The median duration of observation was 34 (4–68)
months. The 5-year survival rate and median survival time
after surgery of patients with pathological stage III/N2
NSCLC was 27.0% and 28.0 months (95% CI, 18.0-60.0),
respectively. The 5-year survival rate of patients with medi-
astinal lymph node metastasis (N2) that had skip medias-
tinal lymph node metastasis (without N1 lymph node
metastasis) was 32.8%; however, the 5-year survival rate of
patients with mediastinal lymph nodes metastasis (N2) with
N1 disease was 28.5%. The prognosis of patients with skip
mediastinal lymph node metastasis showed a tendency for
improved survival, but this was not significant (p = 0.432).
With regard to the total number of involved lymph nodes,
the 5-year survival rate of patients with 5 or less than 5
positive lymph nodes was 40.2%; it was 20.0% for patients
with more than 5 positive lymph nodes (Figure 2). Differ-
ences between the two groups were statistically significant
(p < 0.001). The effects of the type of lung resection were
assessed, and the 5-year survival rate was found to be
33.6% for patients who underwent lobectomy, and 16% for
patients who underwent pneumonectomy (p = 0.001). InFigure 3 Survival curves for NSCLC patients with negative or positive
with ERCC1 negative expression and 20.3% for patients with ERCC1 positivaddition, significant differences were observed in the sur-
vival rates of patients with T1/T2 relative to T3/T4 disease
(p = 0.003). Age, gender and histopathological type did not
affect survival (Table 2). The 5-year survival rates of pa-
tients was 46% for ERCC1 negative expression and 20.3%
for ERCC1 positive expression; this difference was statisti-
cally significant (p = 0.004; Figure 3). Multivariate analysis
of survival in patients with stage III/N2 NSCLC showed
that surgical procedure (pneumonectomy vs. lobectomy;
p = 0.001), number of involved lymph nodes (≤5 vs. >5;
p = 0.001) and ERCC1 protein expression (negative vs.
positive; p = 0.012) were significant prognostic factors
(Table 3). Age, T factor, gender, histology, and skip me-
tastasis did not affect survival.
Discussion
NSCLC represents one of the most common and aggres-
sive solid tumors, and it is difficult to cure. The Japanese
Lung Cancer Registry Study of 6644 resected NSCLC
cases in Japan reported that the 5-year survival rates of
patients with stage IIIA and IIIB were 29.8% and 19.3%,
respectively [18]. The prognosis of N2 NSCLC patients
has remained poor, and most oncologists believed that
surgery alone is not sufficient to cure patients with N2
disease. During the past decade, most patients with N2
have received perioperative chemotherapy to improve their
survival. However, patients with pN2 NSCLC are a hetero-
geneous population, and optimal therapeutic selection forexpression of ERCC1. The 5-year survival rate was 46% for patients
e expression.
Table 3 The results of the multivariate analysis of overall
survival
Variables Overall survival p-Value
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rate for patients with p-stage III/N2 was 27% in the
current series, which is consistent with the Japanese
Lung Cancer Registry Study. This suggested that some
cases can be cured by surgery alone, while others should
be considered for more intensive treatments in order to
potentially achieve a cure. The valuable factors regarding
multimodality therapy for the improvement of prognosis in
stage III/N2 disease are unclear.
Some studies have shown that a single station of
mediastinal-node metastasis was an acceptable prognos-
tic predictor [19], and another study demonstrated that
the highest lymph node involvement, skip metastasis
and single station involvement were associated with
prognosis [20-22]. Skip metastasis in our study was de-
fined as the presence of mediastinal lymph node metas-
tasis (N2 disease) without intralobar and/or hilar nodal
involvement (N1). In our study, the patients with skip
metastasis showed a tendency for improved survival;
however, there was no significant survival differencebetween patients with skip metastasis relative to those
without skip metastasis (p = 0.432).
The present study focused on the number of involved
lymph nodes in regional lymph nodes (N1 and N2). The
5-year survival rate of the patients at stage III/N2 was de-
creased according to the total number of involved lymph
nodes (N1+N2) present. The patients with ≤5 lymph node
metastases had a significantly better prognosis than those
with >5 lymph node metastases. In the multivariate ana-
lysis, the number of involved lymph node was also found
to be a significant independent prognostic factor for pa-
tients with p-stage III/N2 NSCLC.
Surgical intervention still plays a crucial role in se-
lected cases with p-stage III/N2 NSCLC. Lobectomy may
be safely performed following induction therapy while
pneumonectomy may carry a high and possibly un-
acceptable rate of perioperative mortality [23,24]. This
retrospective study tried to clarify the prognostic im-
portance of the type of pulmonary resection in patients
with p-stage III/N2 NSCLC, who underwent complete
dissection of the mediastinal lymph nodes. Multivariate
analysis demonstrated that undergoing pneumonec-
tomy was significantly associated with a shorter overall
survival (OS) (hazard ratio [HR] 2.455; p = 0.001).
The survival outcomes of patients with p-stage III/N2
NSCLC have been poor when they were treated with
surgery alone. Numerous studies have investigated induc-
tion chemotherapy, radiotherapy, and chemoradiotherapy
with the objective of improving the outcome for this high-
risk population. The present status of postoperative
adjuvant chemotherapy for the treatment of completely
resected p-stage III/N2 NSCLC is based on the results of
large-scale phase III trials involving cisplatin-based regi-
mens, such as IALT and ANITA studies, and a recent
individual patient meta-analysis [25-27]. However, the ap-
propriate application and sequence of these treatments is
still the subject of ongoing studies. Thus, new biomarkers
are required for use in treatment decision-making. Cur-
rently, the most frequently reported candidate marker is
ERCC1, implicated in DNA repair.
ERCC1 is the limiting factor in nucleotide excision re-
pair, which removes platinum-DNA adducts. ERCC1
may also be involved in the repair of DNA double-strand
breaks, especially those induced by interstrand cross-
links. It is possible that the presence of ERCC1 reflects
an inherent biologic characteristic of the tumor. The
ERCC1 expression level has recently been reported to be
a prognostic factor in the survival of patients with early
stage NSCLC [8,12]. Our study evaluated the effect of
intratumoral ERCC1 expression on the survival of pa-
tients with completely resected p-stage III/N2 NSCLC.
Results showed that the survival for patients with ERCC1
negative tumors was significantly longer than those for
patients with ERCC1 positive tumors. This suggested
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may be beneficial for ERCC1-negative patients. Olaussen
et al. [12] also reported that ERCC1 protein expression
status was associated with favorable prognosis in patients
treated with cisplatin-base adjuvant chemotherapy, simi-
lar to data reported in another study [28]. Furthermore,
in the multivariate analysis, ERCC1 was identified as an
independent predictor of survival. Further validation of
these findings may help us to choose molecular-based
personalized multimodality therapy.
The limitations of this study were: (I) it was retrospective
and many factors could have influenced survival; (II) the
sample size was limited, so the prognostic significant of
skip metastasis with regard to OS was not confirmed; and
(III) the ERCC1 positive expression rate in our study was
higher than that reported in the IALT trial. Possible ex-
planations might be that ours was a small sample size
retrospective study, and all of the Chinese patients were
diagnosed with p-stage III/N2 NSCLC.
Conclusions
In conclusion, the survival of patients with p-stage III/N2
NSCLC depends on numerous factors, and accurately de-
termining the prognosis of disease in these patients is un-
clear. Therefore, valuable biomarker fitting to determine
the subgroup of patients who have a relatively poor prog-
nosis in the Chinese population is needed. Our study
suggested that the number of involved lymph nodes and
the type of pulmonary resection are significant and inde-
pendent prognostic factors in patients with p-stage III/N2
NSCLC. In addition, the current study revealed that
DNA repair genes may play an important role in the
prognosis of locally advanced NSCLC patients. Therefore,
ERCC1 protein expression might be a useful biological in-
dicator in patients with locally advanced NSCLC when
planning clinical studies by testing the hypothesis of cus-
tomized chemotherapy.
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